Recursion Pharmaceuticals-a (RXRX)

$6.38

+0.49

(+8.32%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Recursion Pharmaceuticals-a Key Statistics

Market Capitalization
$2.5B
Revenue TTM
$65.2M
EBITDA
$-364.2M
Earnings Per Share (EPS)
$-1.54
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-78.49%

Recursion Pharmaceuticals-a share price movements

  • $5.95
    $6.45
    $6.38
    downward going graph

    6.82%

    Downside

    Day's Volatility :7.76%

    Upside

    1.01%

    downward going graph
  • $5.60
    $15.74
    $6.38
    downward going graph

    12.23%

    Downside

    52 Weeks Volatility :64.42%

    Upside

    59.47%

    downward going graph

Recursion Pharmaceuticals-a Returns

PeriodRecursion Pharmaceuticals-aSector (Health Care)Index (Russel 2000)
3 Months
-13.9%
-5.9%
0.0%
6 Months
-25.64%
3.8%
0.0%
1 Year
-9.5%
13.3%
0.0%
3 Years
-66.39%
11.0%
-21.1%

Analyst Recommendation on Recursion Pharmaceuticals-a

Buy
    53%Buy
    46%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Recursion Pharmaceuticals-a(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
6
6
6
Sell
00
00
00

Analyst Forecast on Recursion Pharmaceuticals-a

What analysts predicted

Upside of 54.5%

Current $6.38
Target $9.86

Insights on Recursion Pharmaceuticals-a

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 10.10M → 26.08M (in $), with an average increase of 19.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -97.54M → -95.67M (in $), with an average increase of 2.0% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.7% return, outperforming this stock by 64.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 40.4% return, outperforming this stock by 106.8%

Recursion Pharmaceuticals-a Financials in INR & Dollars

FY19Y/Y Change
Revenue
1.7M
-
Net Income
-62.5M
-
Net Profit Margin
-3.7K%
-
FY20Y/Y Change
Revenue
3.4M
↑ 99.47%
Net Income
-87.9M
↑ 40.55%
Net Profit Margin
-2.6K%
↑ 1079.38%
FY21Y/Y Change
Revenue
10.0M
↑ 193.0%
Net Income
-178.1M
↑ 102.63%
Net Profit Margin
-1.8K%
↑ 794.18%
FY22Y/Y Change
Revenue
39.7M
↑ 296.81%
Net Income
-239.4M
↑ 34.45%
Net Profit Margin
-603.36%
↑ 1177.38%
FY23Y/Y Change
Revenue
44.6M
↑ 12.33%
Net Income
-328.1M
↑ 37.02%
Net Profit Margin
-735.99%
↓ 132.63%
Q2 FY23Q/Q Change
Revenue
11.0M
↓ 9.21%
Net Income
-76.7M
↑ 26.22%
Net Profit Margin
-696.5%
↓ 195.52%
Q3 FY23Q/Q Change
Revenue
10.1M
↓ 8.3%
Net Income
-93.0M
↑ 21.23%
Net Profit Margin
-920.78%
↓ 224.28%
Q4 FY23Q/Q Change
Revenue
10.9M
↑ 7.81%
Net Income
-93.0M
↓ 0.02%
Net Profit Margin
-853.88%
↑ 66.9%
Q1 FY24Q/Q Change
Revenue
13.8M
↑ 26.66%
Net Income
-91.4M
↓ 1.75%
Net Profit Margin
-662.41%
↑ 191.47%
Q2 FY24Q/Q Change
Revenue
14.4M
↑ 4.52%
Net Income
-97.5M
↑ 6.75%
Net Profit Margin
-676.56%
↓ 14.15%
Q3 FY24Q/Q Change
Revenue
26.1M
↑ 80.91%
Net Income
-95.7M
↓ 1.91%
Net Profit Margin
-366.82%
↑ 309.74%
FY19Y/Y Change
Total Assets
101.4M
-
Total Liabilities
225.7M
-
FY20Y/Y Change
Total Assets
298.6M
↑ 194.37%
Total Liabilities
504.9M
↑ 123.7%
FY21Y/Y Change
Total Assets
610.3M
↑ 104.41%
Total Liabilities
67.4M
↓ 86.65%
FY22Y/Y Change
Total Assets
701.3M
↑ 14.9%
Total Liabilities
215.5M
↑ 219.67%
FY23Y/Y Change
Total Assets
653.7M
↓ 6.79%
Total Liabilities
190.3M
↓ 11.7%
Q2 FY23Q/Q Change
Total Assets
666.7M
↑ 6.27%
Total Liabilities
197.7M
↑ 0.28%
Q3 FY23Q/Q Change
Total Assets
630.8M
↓ 5.38%
Total Liabilities
192.9M
↓ 2.47%
Q4 FY23Q/Q Change
Total Assets
653.7M
↑ 3.63%
Total Liabilities
190.3M
↓ 1.35%
Q1 FY24Q/Q Change
Total Assets
557.8M
↓ 14.66%
Total Liabilities
156.7M
↓ 17.64%
Q2 FY24Q/Q Change
Total Assets
775.9M
↑ 39.08%
Total Liabilities
191.4M
↑ 22.16%
Q3 FY24Q/Q Change
Total Assets
726.5M
↓ 6.36%
Total Liabilities
201.9M
↑ 5.5%
FY19Y/Y Change
Operating Cash Flow
-57.0M
-
Investing Cash Flow
-3.9M
-
Financing Cash Flow
120.4M
-
FY20Y/Y Change
Operating Cash Flow
-45.4M
↓ 20.41%
Investing Cash Flow
-8.7M
↑ 123.53%
Financing Cash Flow
246.1M
↑ 104.41%
FY21Y/Y Change
Operating Cash Flow
-158.6M
↑ 249.38%
Investing Cash Flow
-271.7M
↑ 3009.2%
Financing Cash Flow
458.5M
↑ 86.3%
FY22Y/Y Change
Operating Cash Flow
-83.5M
↓ 47.34%
Investing Cash Flow
193.2M
↓ 171.11%
Financing Cash Flow
154.3M
↓ 66.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-67.5M
↓ 7.98%
Investing Cash Flow
-2.1M
↓ 61.55%
Financing Cash Flow
3.8M
↑ 97.03%

Recursion Pharmaceuticals-a Technicals Summary

Sell

Neutral

Buy

Recursion Pharmaceuticals-a is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Recursion Pharmaceuticals-a Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
-5.34%
-25.64%
-9.5%
-66.39%
-77.6%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.6%
-21.9%
-6.64%
15.35%
104.57%
Biontech Se
Biontech Se
5.89%
29.49%
21.63%
-66.7%
449.23%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-10.87%
72.69%
54.71%
40.39%
116.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.23%
5.31%
32.35%
144.36%
109.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
NA
NA
NA
-1.54
-0.78
-0.36
NA
1.83
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.66
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Recursion Pharmaceuticals-a
Recursion Pharmaceuticals-a
Buy
$2.5B
-77.6%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
104.57%
18.66
33.61%
Biontech Se
Biontech Se
Buy
$28.9B
449.23%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
116.61%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.6B
109.5%
32.84
-4.51%

Recursion Pharmaceuticals-a Institutional Holdings

  • ARK Investment Management LLC

    11.43%

  • Baillie Gifford & Co Limited.

    8.81%

  • Vanguard Group Inc

    8.47%

  • BlackRock Inc

    6.04%

  • RA Capital Management, LLC

    5.37%

  • Mubadala Investment Company PJSC

    4.53%

Corporate Announcements

  • Recursion Pharmaceuticals-a Earnings

    Recursion Pharmaceuticals-a’s price-to-earnings ratio stands at None

    Read More

About Recursion Pharmaceuticals-a

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.

Organization
Recursion Pharmaceuticals-a
Employees
500
CEO
Dr. Christopher C. Gibson Ph.D.
Industry
Services

FAQs